Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Accord EMENA Chief Says Industry Is Pushing Back On Pressures

Inflation, Pricing Constraints And Shortages Follow Fallout From Pandemic

Executive Summary

Amid continuing cost inflation, downwards pressure on prices, industry shortages and other supply-chain disruptions, Paul Tredwell – Accord’s executive vice-president for the Europe, Middle East and North Africa region – talks about how the off-patent industry is seeking to improve its operating environment.

You may also be interested in...

Accord Sees Benefits From Unique Portfolio

With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.

Industry Speaks Out On Global Antibiotics Shortages

Responding to shortages of antibiotics seen around the world, the IGBA has insisted that the generics industry is working to address spikes in demand and has set out a series of recommendations to mitigate the situation. Meanwhile, US association the AAM has countered suggestions that supply issues are due to a “broken generic drug market.”

Accord Unveils New Ventures After A Year Of Change

A year after taking up the lead for Accord in the EMENA region, Paul Tredwell talks to Generics Bulletin in detail about the changes that he has already overseen in the role, as well as unveiling a number of new business initiatives, acquisitions and appointments that form part of his long-term growth strategy.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts